BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.) 

9640 Medical Center Drive

Rockville  Maryland  20850  U.S.A.
Phone: 240-864-2600 Fax: 240-864-2601


View Clinical Trials from BioPharm Insight

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism drugs that target disease cells directly and the blood vessels that nourish them. We are focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes.

EntreMed’s goal is to develop and commercialize therapeutics based on the Company’s scientific expertise in angiogenesis, cell cycle regulation, cell signaling, and inflammation — processes vital to the progression of cancer and other diseases. The Company’s three clinical product candidates for oncology are based on these mechanisms. The Company’s expertise has also led to the identification of new molecules, including new chemical entities that cause apoptosis and cell cycle arrest, as well as new chemical entities associated with Aurora/angiogenesis inhibition and histone deacetylase (HDAC) inhibition, important targets in the treatment of oncology.

EntreMed is developing orally-administered, small molecule compounds that have broad therapeutic and commercial potential in oncology and inflammatory diseases. In order to further advance its commercial objectives, EntreMed may seek strategic alliances, licensing relationships and co-development partnerships with other companies to develop compounds for both oncology and non-oncology therapeutic areas.

Our Product Candidates

MKC-1, a novel, orally-active cell cycle inhibitor, is currently in multiple Phase 1 and Phase 2 clinical trials, including metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), hematological cancers, ovarian and endometrial cancer, and pancreatic cancer.

ENMD-1198, a potent, orally-active, antimitotic agent, is currently in a Phase 1 dose-escalation clinical trial in patients with refractory solid tumors. Completion of the study is expected around mid-2008 with a further trial expected in the second half of 2008.

ENMD-2076 is an orally-active selective kinase inhibitor with a unique kinase profile, including antiproliferative activity and inhibition of angiogenesis. EntreMed’s IND has been accepted by the FDA and a Phase 1 study in solid tumors is expected to enroll patients in early 2Q08.

Panzem® (2-methoxyestradiol, 2ME2) is moving forward in rheumatoid arthritis based on the knowledge gained from the oncology development effort and favorable preclinical research results showing that 2ME2 has disease modifying or “DMARD” activity. The FDA has accepted EntreMed’s IND for 2ME2 in RA, which included an extensive human safety dossier in 300 patients from prior oncology studies. Panzem® for RA represents a safe, orally administered, small molecule alternative to current biologicals and a potential “first-in-class” cross-over opportunity from oncology. The Company plans to initiate a normal volunteer clinical trial in 2008 and seek a development partner to manage larger multi-arm Phase 2 and Phase 3 studies.

Senior Management

James S. Burns, President & CEO
Dane Saglio, Chief Financial Officer
Cynthia Wong Hu, Vice President, General Counsel and Corporate Secretary
Carolyn F. Sidor, M.D., MBA, Vice President and Chief Medical Officer
Kenneth W. Bair, Ph.D., Senior Vice President, Research and Development

Ginny Dunn
Associate Director, Corporate Communications & Investor Relations
Phone: 240-864-2643
Fax: 240-864-2601

 Key Statistics

Ownership: Public

Web Site: CASI Pharmaceuticals
Employees: 56 employees
Symbol: ENMD

 Company News
CASI Pharmaceuticals  (ENMD) Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer 3/4/2015 6:53:04 AM
CASI Pharmaceuticals  (ENMD) To Present At The 27th Annual ROTH Conference 3/3/2015 10:28:11 AM
CASI Pharmaceuticals  (ENMD) Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For The Treatment Of Patients With Fibrolamellar Carcinoma (FLC) 2/9/2015 11:48:22 AM
CASI Pharmaceuticals  (ENMD)To Present At The 17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/2/2015 11:41:22 AM
CASI Pharmaceuticals  (ENMD) Highlights 2014 Accomplishments And 2015 Milestones 1/16/2015 9:48:47 AM
CASI Pharmaceuticals  (ENMD) To Hold Business Update Conference Call And Webcast On January 6th 12/23/2014 8:19:29 AM
CASI Pharmaceuticals  (ENMD) Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 12/17/2014 9:53:11 AM
CASI Pharmaceuticals  (ENMD) Reports Third Quarter 2014 Financial Results 11/14/2014 8:08:44 AM
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma 11/12/2014 7:13:10 AM
CASI Pharmaceuticals  (ENMD) Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 9/23/2014 8:32:46 AM